HOME >> BIOLOGY >> NEWS
Sunlight converts common anti-bacterial agent to dioxin

MINNEAPOLIS / ST. PAUL--Sunlight can convert triclosan, a common disinfectant used in anti-bacterial soaps, into a form of dioxin, and this process may produce some of the dioxin found in the environment, according to research at the University of Minnesota. The researchers said that although the dioxin was a relatively benign form, treating wastewater with chlorine could possibly lead to the production of a much more toxic species of dioxin. The study is in press in the Journal of Photochemistry and Photobiology A: Chemistry.

It had already been known that triclosan could be converted to dioxin in the laboratory, and it was also known that sunlight causes triclosan to degrade in the environment. But it had not been known that the natural degradation resulted in dioxin, said researchers Kristopher McNeill, an assistant professor of chemistry, and William Arnold, assistant professor of civil engineering. They discovered that the reaction could occur in Mississippi River water exposed to ultraviolet light.

"This form of dioxin is at least 150,000 times less toxic than the most dangerous form," said McNeill. "But repeated exposure to chlorine, perhaps in water treatment facilities, could chlorinate triclosan. After chlorinated triclosan is discharged from the facility, sunlight could convert it into more toxic dioxins. Such a process could be a source of highly toxic dioxin in the environment."

"This study also shows that the disappearance of a pollutant such as triclosan doesn't necessarily mean an enviromental threat has been removed," said Arnold. "It may just have been converted into another threat."

The researchers began their study after reading numerous environmental studies that reported the presence of pharmaceutical compounds in surface waters around the nation. McNeill and Arnold decided that the logical next step was to examine the natural processes that led to the loss of such materials in the environment. Last year, the U.
'"/>

Contact: Deane Morrison
morri029@umn.edu
612-624-2346
University of Minnesota
14-Apr-2003


Page: 1 2

Related biology news :

1. Sunlight, PCB exposure enhance skin cancer chances
2. How Nature Harvests Sunlight
3. Researchers discover new oceanic bacterial photopigment that converts light into biochemical energy
4. New process converts municipal waste into commodities and fuel
5. Most recent common ancestor of all living humans surprisingly recent
6. Hidden diversity: DNA barcoding reveals a common butterfly is actually 10 different species
7. European common frog found to use novel mating strategy
8. Genetic clues found for common congenital brain disorder
9. Stanford researchers findings may shed light on common, deadly birth defect
10. U-M scientists find common virus in human prostate tissue
11. Scientists suggest framework for epigenetics in common disease

Post Your Comments:
*Name:
*Comment:
*Email:
TAG: Sunlight converts common anti bacterial agent dioxin

(Date:12/11/2014)... DUBLIN , Dec. 09, 2014 Research ... http://photos.prnewswire.com/prnh/20130307/600769 ( http://www.researchandmarkets.com/research/9ql3kr/biometrics_market ) ... Market in India 2015-2019" report to their ... in this market is the adoption of multimodal ... one characteristic of an individual for verification and ...
(Date:12/11/2014)... Minn. , Dec. 10, 2014  Data ... physiologic monitoring, has released a new series of ... of preclinical toxicology researchers. M series, part of ... toxicologists collect the best possible physiologic data when ... Adding functional endpoints to toxicology studies has ...
(Date:12/10/2014)... 2014  Valencell, a leader in performance biometric data ... demand from its licensees for highly accurate, clinically validated ... solely coming from fitness and health sectors, but first ... wearable is only as useful as the biometric data ... driver in long-term mass consumer adoption of wearable products," ...
Breaking Biology News(10 mins):Biometrics Market in India 2015-2019: Key Vendors are 3M Cogent, NEC, Safran and Suprema 2New telemetry implants expected to change how large animal toxicology studies are conducted 2Wearable Technology Products Demand Highly Accurate Biometric Technology 2
(Date:12/19/2014)... 2014 LayerBio is an MIT spin-off ... care. The National Eye Institute (NEI) at the National ... I SBIR grant to develop a drug-eluting intraocular lens ... common cause of vision loss in people over age ... to Dr. Ken Mandell, LayerBio’s Founder and CEO, "There ...
(Date:12/19/2014)... The empty capsules market is ... population and technological innovations in the empty capsules ... catalysing the growth of the empty capsules market. ... , Scope of Report , The report will ... entrants/smaller firms to gauge the pulse of the ...
(Date:12/19/2014)... YORK , Dec. 18, 2014 Relmada ... therapies for the treatment of chronic pain, announced the ... today. "This was a transformational year in ... promising future for our company," said Sergio Traversa ... year, we have executed on key financial, human resource ...
(Date:12/17/2014)... Ipsen Biopharmaceuticals, Inc., an affiliate ... IPSEY), today announced that Somatuline® Depot® (lanreotide) ... approved by the U.S. Food and Drug Administration ... (GEP-NETs) in adult patients with unresectable, well or ... improve progression-free survival (PFS). , “The approval of ...
Breaking Biology Technology:LayerBio Awarded NIH Grant to Develop a Drug Delivery Device for Cataract Surgery 2Empty Capsules Market Hit to Reach $1,820 Million by 2019 - New Research Report by MarketsandMarkets 2Empty Capsules Market Hit to Reach $1,820 Million by 2019 - New Research Report by MarketsandMarkets 3Empty Capsules Market Hit to Reach $1,820 Million by 2019 - New Research Report by MarketsandMarkets 4Relmada Therapeutics Announces Results of Annual Shareholders Meeting 2Ipsen Announces the FDA Approval of Somatuline® Depot® (lanreotide) Injection for the Treatment of Gastroenteropancreatic Neuroendocrine Tumors 2Ipsen Announces the FDA Approval of Somatuline® Depot® (lanreotide) Injection for the Treatment of Gastroenteropancreatic Neuroendocrine Tumors 3Ipsen Announces the FDA Approval of Somatuline® Depot® (lanreotide) Injection for the Treatment of Gastroenteropancreatic Neuroendocrine Tumors 4Ipsen Announces the FDA Approval of Somatuline® Depot® (lanreotide) Injection for the Treatment of Gastroenteropancreatic Neuroendocrine Tumors 5Ipsen Announces the FDA Approval of Somatuline® Depot® (lanreotide) Injection for the Treatment of Gastroenteropancreatic Neuroendocrine Tumors 6Ipsen Announces the FDA Approval of Somatuline® Depot® (lanreotide) Injection for the Treatment of Gastroenteropancreatic Neuroendocrine Tumors 7Ipsen Announces the FDA Approval of Somatuline® Depot® (lanreotide) Injection for the Treatment of Gastroenteropancreatic Neuroendocrine Tumors 8
Cached News: